Kingworld Medicines Group Limited (HKG:1110)
Hong Kong · Delayed Price · Currency is HKD 0.3950
0.00 (0.00%)
Oct 2, 2026, 3:57 PM HKT
Kingworld Medicines Group Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 234 | 307 | 270 | 392 | 529 | 473 | |
Market Cap Growth | -23.67% | 13.61% | -31.19% | -25.88% | 11.84% | 1.33% |
Enterprise Value | 587 | 594 | 465 | 522 | 655 | 601 |
Last Close Price | 0.40 | 0.52 | 0.43 | 0.56 | 0.74 | 0.62 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.62 | 24.42 | 6.10 | 9.34 | 20.58 | 12.71 |
Forward PE | - | 9.16 | 9.16 | 9.16 | 9.16 | 9.16 |
PS Ratio | 0.26 | 0.30 | 0.24 | 0.33 | 0.49 | 0.46 |
PB Ratio | 0.31 | 0.40 | 0.36 | 0.51 | 0.67 | 0.54 |
P/TBV Ratio | 0.40 | 0.52 | 0.46 | 0.67 | 0.89 | 0.75 |
P/FCF Ratio | 260.22 | 5.02 | 2.68 | - | 5.03 | 16.85 |
P/OCF Ratio | 5.28 | 3.26 | 1.87 | 8.42 | 2.51 | 4.75 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.65 | 0.58 | 0.41 | 0.44 | 0.61 | 0.58 |
EV/EBITDA Ratio | 5.59 | 7.41 | 4.18 | 5.35 | 5.39 | 5.08 |
EV/EBIT Ratio | 7.83 | 9.41 | 4.69 | 6.02 | 7.21 | 6.87 |
EV/FCF Ratio | 652.62 | 9.72 | 4.61 | - | 6.22 | 21.40 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.67 | 0.63 | 0.57 | 0.51 | 0.42 | 0.33 |
Debt / EBITDA Ratio | 5.19 | 5.25 | 3.55 | 3.59 | 2.45 | 2.25 |
Debt / FCF Ratio | 562.42 | 7.90 | 4.25 | - | 3.12 | 10.44 |
Net Debt / Equity Ratio | 0.38 | 0.23 | 0.22 | 0.23 | 0.05 | 0.06 |
Net Debt / EBITDA Ratio | 3.39 | 2.21 | 1.46 | 1.81 | 0.32 | 0.42 |
Net Debt / FCF Ratio | 320.60 | 2.90 | 1.61 | -2.54 | 0.37 | 1.77 |
Asset Turnover | 0.58 | 0.64 | 0.77 | 0.83 | 0.77 | 0.69 |
Inventory Turnover | 4.71 | 5.28 | 6.65 | 7.89 | 7.10 | 4.93 |
Quick Ratio | 0.68 | 0.78 | 0.87 | 0.92 | 0.90 | 1.00 |
Current Ratio | 1.05 | 1.09 | 1.18 | 1.27 | 1.15 | 1.35 |
Return on Equity (ROE) | 5.18% | 5.58% | 10.60% | 8.84% | 6.16% | 7.32% |
Return on Assets (ROA) | 2.70% | 2.48% | 4.23% | 3.78% | 4.05% | 3.61% |
Return on Invested Capital (ROIC) | 3.82% | 4.50% | 8.45% | 6.50% | 6.95% | 7.08% |
Return on Capital Employed (ROCE) | 6.90% | 6.50% | 10.30% | 9.00% | 11.10% | 9.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.66% | 4.09% | 16.39% | 10.70% | 4.86% | 7.87% |
FCF Yield | 0.38% | 19.93% | 37.36% | -17.77% | 19.88% | 5.94% |
Dividend Yield | - | - | 7.36% | 6.02% | 3.35% | 3.84% |
Payout Ratio | 158.20% | 160.84% | 47.60% | 36.54% | 58.45% | 10.89% |
Buyback Yield / Dilution | -4.02% | -1.78% | 2.66% | 2.49% | -0.04% | 1.29% |
Total Shareholder Return | -4.02% | -1.78% | 10.02% | 8.51% | 3.32% | 5.12% |